| HRA003138
(Open Access)
|
our major aim of the study is to identify the subset of patients who may benefit from EGFR-TKIs therapy, and hence to design appropriate treatment strategies for optimized clinical outcome. Specifically, the biopsied samples of lung cancer patients are subjected to quantitative detection of EGFR mutations (L858R, 19del) using the fluorescent probe HX103 and FACS analysis. Combined with the results from gene sequencing and HX103 labeling, it will allow us to rapid and accurate determine EGFR mutations in lung cancer patients. |
